

Product Quality Microbiology Assessment: The What and The Where

Marla Stevens-Riley, Ph.D.

Master Microbiology Reviewer
Division of Microbiology Assessment
Office of Process and Facilities
Office of Pharmaceutical Quality
CDER/FDA

Regulatory Education for Industry
April 5, 2017

Presentation Overview

- **The What**
 - Product Quality Microbiology defined
 - Mini lesson about product quality microbiology
 - Types of submissions reviewed
- **The Where**
 - Location in Common Technical Document

Product Quality Microbiology Defined

- **What it is:**
 - Microbiology of the manufacturing processes
 - Control of or removal of microbes during manufacturing
 - Part of Chemistry, Manufacturing & Controls (CMC)
 - Combination of microbiology and engineering

Product Quality Microbiology Defined

- **What it is not:**
 - Not clinical microbiology
 - Not evaluation of the efficacy of antimicrobials

Product Quality Microbiology Defined

- **Focus:** Processes that **will be used** for commercial production
- **Not a focus:** Processes and equipment that **were used** for the exhibit batch

Product Quality Microbiology Defined

- **Sterile versus non-sterile drug products**
 - Sterile: no microbes allowed in final product
 - Non-sterile: microbes allowed in final product
 - Sterile vs. non-sterile products:
 - Location, location, location
 - Indication, indication, indication
- If Reference Listed Drug is sterile, then generic drug is sterile

Product Quality Microbiology Defined

- **Sterile products include:**
 - Injectables, ophthalmics, otics, inhalation solutions
 - Sometimes topicals and orals
- **Non-sterile products include:**
 - Orals, nasal sprays, topicals

Product Quality Microbiology Defined

- **Assures there are controls for microbes and by-products**
 - Raw materials, packaging, equipment
 - Manufacturing processes
 - Environment
- **Assures effectiveness of reduction, removal, or destruction**
 - Washing, filtration, heat, radiation, gas
 - Evaluation of validation and process simulations

Mini Lesson

- **Sterile products**

- Two methods to manufacture a sterile product

- Aseptic Processing (aseptic filling)

- Components sterilized separately, then brought together

- Higher risk

- Terminal Sterilization

- All components brought together, then sterilized

- Lower risk

Mini Lesson

- **Sterile products**

- Two methods to manufacture a sterile product

- Aseptic Processing (aseptic filling)

- Components sterilized separately, then brought together


- Higher risk

- Terminal Sterilization


- All components brought together, then sterilized

- Lower risk

Mini Lesson



Mini Lesson



Submissions Reviewed

- **Applications**
 - ANDAs, NDAs, BLAs, INDs
 - Originals, amendments, supplements
 - Drug Master Files
 - Meeting packages
 - Controlled correspondence (generics only)
 - Inquiries

Location of Information

- **Module 1-Regional**
 - 1.1 Forms
 - 1.2 Cover letter
 - 1.4 References
 - Letter of Authorization for DMFs!!!

Location of Information

- **Module 1-Regional**
 - 1.14.1 Draft Labeling
 - Container label: Dose
 - Package insert:
 - Reconstitution and/or dilution and storage
 - Pharmacy Bulk Package information
 - Patient dosage and administration

Location of Information

- **Module 2-CTD Summaries**
 - 2.3 Quality Overall Summary
 - Optional
 - Question-based Review for terminally sterilized products
 - Question-based Review for aseptically processed products

Location of Information

- **Module 3.2.P. Drug Product**
 - P.1 Description and Composition of Drug Product
 - Components
 - Container closure system
 - P.2 Pharmaceutical Development
 - P.2.5 Microbiological Attributes
 - Antimicrobial effectiveness testing
 - Container closure integrity testing

Location of Information

- **Module 3.2.P.3 Manufacture**
 - P.3.1 Manufacturers
 - Manufacture for commercial production
 - Testing for release and stability
 - P.3.3 Description of the Manufacturing Process and Process Controls
 - Commercial production

Location of Information

- **Module 3.2.P.3 Manufacture**
 - P.3.5 Process Validation
 - Validation studies for proposed commercial production processes
 - Sterilization
 - Depyrogenation
 - Process simulations
- Validation assures that you can do what you say you will do

Location of Information

- **Module 3.2.P.5 Control of Drug Product**
 - P.5.1 Specification
 - All sterile products: Sterility Test (USP <71>)
 - All sterile injectable products: Sterility Test and Endotoxins Test (USP <85>)
 - P.5.2 Analytical Procedures
 - P.5.3 Validation of Analytical Procedures

Location of Information

- **Module 3.2.P.8 Stability**
 - P.8.1 Stability Summary and the Conclusion
 - P.8.2 Post-approval Stability Protocol and Stability Commitment
 - Sterility Test (or Container Closure Integrity)
 - Antimicrobial Effectiveness Test (USP <51>)
 - P.8.3 Stability Data

Location of Information

- **3.2 Regional Information**
 - R.1 Executed batch records
 - R.2 Comparability protocol
- **A.2 Adventitious Agents Safety Evaluation**
 - BSE/TSE documentation
 - Viral clearance studies

References

- MaPP 5040.1: *Product Quality Microbiology Information in the Common Technical Document-Quality (CTD-Q)*

<https://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/manualofpoliciesprocedures/default.htm>

- Guidance for Industry: *Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products*

<https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm064983.htm>

References

- *Question-based Review (QbR) for Sterility Assurance of Terminally Sterilized Products: Quality Overall Summary Outline*

<http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/UCM276168.pdf>

- *Question-based Review (QbR) for Sterility Assurance of Aseptically Processed Products: Quality Overall Summary Outline*

<http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/ucm120955.htm>



Thank You

Marla Stevens-Riley, Ph.D.

marla.stevens-riley@fda.hhs.gov

Please complete the session survey:

surveymonkey.com/r/GDF-D2S15